Immunomethylomic profiles of long-term head and neck squamous cell carcinoma survivors on immune checkpoint inhibitors

被引:1
|
作者
Lee, Min Kyung [1 ]
Zhang, Ze [1 ]
Sehgal, Kartik [2 ]
Butler, Rondi [3 ,4 ]
Stolrow, Hannah [1 ]
Ramush, Geat [3 ,4 ]
Shirai, Keisuke [5 ]
Koestler, Devin C. [6 ]
Salas, Lucas A. [1 ]
Wiencke, John K. [7 ]
Haddad, Robert [2 ]
Kelsey, Karl T. [3 ,4 ]
Christensen, Brock C. [1 ,8 ,9 ]
机构
[1] Geisel Sch Med Dartmouth, Dept Epidemiol, Lebanon, NH 03755 USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[3] Brown Univ, Dept Epidemiol, Sch Publ Hlth, Providence, RI 02903 USA
[4] Brown Univ, Dept Pathol & Lab Med, Sch Med, Providence, RI 02903 USA
[5] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA
[6] Univ Kansas, Med Ctr, Dept Biostat & Data Sci, Kansas City, KS 66103 USA
[7] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
[8] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03755 USA
[9] Geisel Sch Med Dartmouth, Dept Community & Family Med, Lebanon, NH 03755 USA
基金
美国国家卫生研究院;
关键词
DNA methylation; head and neck squamous cell carcinoma; immune checkpoint inhibitors; immune profiles; immunomethylomics; methylation cytometry; MEMORY T-CELLS; DNA METHYLATION;
D O I
10.1080/17501911.2024.2343274
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Aim: This study addresses the challenge of predicting the response of head and neck squamous cell carcinoma (HNSCC) patients to immunotherapy. Methods: Using DNA methylation cytometry, we analyzed the immune profiles of six HNSCC patients who showed a positive response to immunotherapy over a year without disease progression. Results: There was an initial increase in CD8 T memory cells and natural killer cells during the first four cycles of immunotherapy, which then returned to baseline levels after a year. Baseline CD8 T cell levels were lower in HNSCC immunotherapy responders but became similar to those in healthy subjects after immunotherapy. Conclusion: These findings suggest that monitoring fluctuations in immune profiles could potentially identify biomarkers for immunotherapy response in HNSCC patients.
引用
收藏
页码:799 / 807
页数:9
相关论文
共 50 条
  • [21] Influence of Immune Microenvironment on Diagnosis and Prognosis of Head and Neck Squamous Cell Carcinoma
    Liu, Guohong
    Yuan, Chunjue
    Ma, Jiaojiao
    Pan, Yunbao
    Xu, Haibo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials
    Dang, Shoutao
    Zhang, Shurong
    Zhao, Jingyang
    Li, Xinyu
    Li, Wei
    CANCER MEDICINE, 2023, 12 (20): : 20277 - 20286
  • [23] Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors
    Stern, Peter L.
    Dalianis, Tina
    VIRUSES-BASEL, 2021, 13 (07):
  • [24] Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
    Jiao, Ruidi
    Luo, Hui
    Xu, Wenbo
    Ge, Hong
    ONCOTARGETS AND THERAPY, 2019, 12 : 6023 - 6032
  • [25] Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis
    Takenaka, Yukinori
    Oya, Ryohei
    Takemoto, Norihiko
    Inohara, Hidenori
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2022, 44 (05): : 1237 - 1245
  • [26] Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors
    Pan, Cassie
    Ng, Kevin
    Voutsinas, Jenna
    Barber, Brittany
    Rizvi, Zain H.
    Marchiano, Emily
    Ferrandino, Rocco M.
    Futran, Neal
    Laramore, George E.
    Liao, Jay J.
    Parvathaneni, Upendra
    Panjwani, Neil
    Martins, Renato G.
    Rodriguez, Cristina P.
    Wu, Qian
    BMC CANCER, 2024, 24 (01)
  • [27] Panoramic analysis of cell death patterns reveals prognostic and immune profiles of head and neck squamous cell carcinoma
    Liu, Xinyu
    Miao, Rui
    Liu, Kui
    Xie, Qun
    Zheng, Penghui
    Zhu, Junai
    Zhang, Ying
    Peng, Fusen
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (05):
  • [28] Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma
    Jin, Zhao
    Cao, Yanshuo
    Lu, Zhihao
    Liu, Chang
    Shen, Lin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 137
  • [29] Prognostic implication of proteomic profiles in head and neck squamous cell carcinoma
    Wu, Donglei
    Gong, Pu
    Zeng, Qing
    Zhang, Wenhao
    Xie, Fei
    Zhou, Xincai
    CLINICA CHIMICA ACTA, 2020, 509 : 304 - 309
  • [30] Risk Factors for Progressive Disease After Immune Checkpoint Inhibitor Therapy in Head and Neck Squamous Cell Carcinoma
    Jang, Seo Yoon
    Lee, Yun-Gyoo
    Chun, Sang Hoon
    Park, Ji Hyun
    Park, Keon Uk
    Chang, Hyun
    Lee, Keun-Wook
    Kim, Hye Ryun
    Shin, Seong Hoon
    An, Ho Jung
    Lee, Kyoung Eun
    Hwang, In Gyu
    Ahn, Myung-Ju
    Kim, Sung-Bae
    Keam, Bhumsuk
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025,